Candidemia
Antifungal medicine VFEND receives U.S. FDA approval for blood infection
Published in Drug Week, January 28th, 2005
Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of its extended-spectrum antifungal VFEND (voriconazole; IV for injection, tablets, and oral suspension) for the treatment of candidemia in nonneutropenic patients (those without low white blood cell counts) and the following Candida infections: disseminated (deep tissue) infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Bloodstream infections caused by Candida (candidemia) are the fourth most common type of hospital-acquired bloodstream infections in the Unites States and have the highest mortality rate.
According to the U.S. Centers...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-01-28)
More Articles from Drug Week
- Anal Fissures
U.S. FDA issues not approvable letter for Cellegesic - Antimicrobials
Antimicrobial and antioxidant activities of medicinal plants reviewed - Breast Cancer
New findings in breast cancer described - Clinical Trials
Company provides update on cancer and HIV clinical-development programs - Depression
European drug review group meets on paroxetine and other SSRIs - Drug Development
FDA grants approval for Enjuvia for vasomotor symptoms - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
